Itraconazole, Quantitative by LC-MS/MS

Also known as: ITRACONAZ

Clinical Use

Use

Itraconazole is an azole antifungal drug indicated to treat fungal infections. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. The pharmacokinetics of itraconazole are influenced by drug-drug interactions when coadministered with drugs metabolized by cytochrome P450 3A4 enzyme. Itraconazole and hydroxyitraconazole concentrations combined should not exceed 10 ug/mL. Adverse effects may include nausea, abdominal pain, and congestive heart failure.

Special Instructions

Not provided.

Limitations

No specific therapeutic range has been established for hydroxyitraconazole. The test results can be affected by the timing of the specimen draw, especially with respect to steady-state concentration. Drug-drug interactions, especially with drugs metabolized by cytochrome P450 3A4 enzyme, can influence itraconazole levels, necessitating careful monitoring.

Test Details

New York Approved

Methodology

Mass Spectrometry

Biomarkers

Hydroxyitraconazole

Analyte

Hydroxyitraconazole

Concentration / Level • Categorical (e.g., Positive / Negative / Indeterminate)

Itraconazole

Analyte

Itraconazole (trough) - Localized Infection

Concentration / Level • Categorical (e.g., Positive / Negative / Indeterminate)

Itraconazole (trough) - Systemic Infection

Concentration / Level • Categorical (e.g., Positive / Negative / Indeterminate)

LOINC Codes

Order Codes

10989-2 - Itraconaz SerPl-mCnc
18337-6 - OH-Itraconaz SerPl-mCnc

Result Turnaround Time

1-6 days

Specimen

Serum

Volume

1 mL

Minimum Volume

0.6 mL

Container

Transfer to an ARUP Standard Transport Tube.

Collection Instructions

No specific patient preparation. Timing of specimen collection: Pre-dose (trough) draw at steady state concentration. Separate from cells ASAP or within 2 hours of collection.